Comparative Pharmacology
Head-to-head clinical analysis: MITOMYCIN versus MUTAMYCIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MITOMYCIN versus MUTAMYCIN.
MITOMYCIN vs MUTAMYCIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Mitomycin is an alkylating agent that inhibits DNA synthesis by cross-linking DNA strands after undergoing enzymatic or chemical bioreduction. It produces oxygen radicals and causes DNA fragmentation, leading to cell cycle arrest and apoptosis.
Cross-links DNA strands, inhibiting DNA synthesis and function.
20 mg/m2 IV as a single dose every 6-8 weeks.
20 mg/m² intravenously every 6 to 8 weeks, as a single bolus dose.
None Documented
None Documented
Terminal elimination half-life: 23–78 min (mean ~50 min) in patients with normal renal function; prolonged in renal impairment.
Clinical Note
moderateMitomycin + Digoxin
"Mitomycin may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateMitomycin + Digitoxin
"Mitomycin may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateMitomycin + Deslanoside
"Mitomycin may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderateMitomycin + Acetyldigitoxin
"Mitomycin may decrease the cardiotoxic activities of Acetyldigitoxin."
Terminal half-life: 30-60 minutes; clinically, rapid clearance necessitates IV bolus administration.
Renal: ~10% unchanged; hepatic metabolism; biliary/fecal: 30-40% as metabolites. Total elimination: ~80% within 24h.
Primarily hepatic metabolism; approximately 10-30% excreted unchanged in urine; small amount in bile.
Category D/X
Category C
Antitumor Antibiotic
Antitumor Antibiotic